Backhouse C I, Platt J, Crawford R J, Allman S
Medical Department, Rorer Health Care Ltd., Eastbourne, England.
Curr Med Res Opin. 1988;10(10):690-8. doi: 10.1185/03007998809111120.
Forty-four patients with mild to moderate essential hypertension were entered in an open study to compare the efficacy and tolerability of the two diuretic combinations, frusemide (40 mg) plus amiloride (5 mg) and hydrochlorothiazide (50 mg) plus amiloride (5 mg), as first-line treatment. After a 2-week run-in period when no antihypertensive medication was given, patients were randomized to receive one or other combination at a dose of 1 tablet daily for 2 weeks. Patients either remained on this regimen for a further 8 weeks or, if their blood pressure was not controlled, dosage was increased to 2 tablets daily. In the latter case, patients were re-assessed after 2 weeks, and those who showed a positive response remained in the study for 8 additional weeks. In the 36 patients assessed (18 in each group), both treatments were found to reduce blood pressure effectively in a high percentage of patients treated. Hydrochlorothiazide/amiloride, however, caused a significant reduction in both plasma potassium and sodium levels whereas frusemide/amiloride did not. More adverse events were reported by patients taking frusemide/amiloride, but the majority of these were trivial.
44例轻度至中度原发性高血压患者进入一项开放性研究，以比较两种利尿剂组合，即呋塞米（40毫克）加阿米洛利（5毫克）和氢氯噻嗪（50毫克）加阿米洛利（5毫克）作为一线治疗的疗效和耐受性。在为期2周的导入期内未给予抗高血压药物，之后患者被随机分组，每天服用1片其中一种组合药物，持续2周。患者要么继续该治疗方案8周，要么如果血压未得到控制，则将剂量增加至每天2片。在后一种情况下，2周后对患者进行重新评估，那些显示出阳性反应的患者再继续研究8周。在评估的36例患者（每组18例）中，发现两种治疗方法都能使大部分接受治疗的患者有效降低血压。然而，氢氯噻嗪/阿米洛利导致血浆钾和钠水平显著降低，而呋塞米/阿米洛利则没有。服用呋塞米/阿米洛利的患者报告的不良事件更多，但其中大多数都不严重。
